Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care
Adverse events considered non‐serious · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes adverse events considered non‐serious (number of participants) compared with best supportive care alone (very low certainty).
1 finding from 1 review
- RR 2 [1.47, 2.72]1 study · 129 participantsVery low